Outlook Therapeutics Q1 loss widens to $18.7M; PDUFA goal date August 29, 2023

Outlook Therapeutics, Inc.

2023-Q1 EPS reported -$0.08

Net loss $18.7M ($0.08/share) vs $14.5M ($0.08) in Q1 fiscal 2022.
Cash and equivalents $52.3M; raised $24M equity and $30M convertible note in Dec 2022.
FDA PDUFA goal date for ONS-5010 (wet AMD) set for August 29, 2023.
Pre-launch commercial activities underway; partnership with AmerisourceBergen.
EMA MAA accepted for ONS-5010; decision expected early 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Outlook Therapeutics, Inc. reported fiscal first quarter ended December 31, 2022 results: net income $18.7 million, or $0.08 per basic and diluted share, EPS $0.08 per basic and diluted share.

Period: fiscal first quarter ended December 31, 2022
Net income: $18.7 million, or $0.08 per basic and diluted share
EPS: $0.08 per basic and diluted share
Result: reported results

Exact text from the filing

On February 14, 2023, Outlook Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for its first fiscal quarter ended December 31, 2022.

View on SEC.gov

20 earnings releases filed in the last 30 days. Browse all earnings releases →

Outlook Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-020751

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.